NO20045220L - Heterocykliske inhibitorer for kinaser - Google Patents

Heterocykliske inhibitorer for kinaser

Info

Publication number
NO20045220L
NO20045220L NO20045220A NO20045220A NO20045220L NO 20045220 L NO20045220 L NO 20045220L NO 20045220 A NO20045220 A NO 20045220A NO 20045220 A NO20045220 A NO 20045220A NO 20045220 L NO20045220 L NO 20045220L
Authority
NO
Norway
Prior art keywords
kinases
heterocyclic inhibitors
heterocyclic
inhibitors
Prior art date
Application number
NO20045220A
Other languages
English (en)
Other versions
NO330043B1 (no
Inventor
Rajeev S Bhide
Robert M Borzilleri
Zhen-Wei Cai
Ligang Qian
John S Tokarski
Peter Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20045220L publication Critical patent/NO20045220L/no
Publication of NO330043B1 publication Critical patent/NO330043B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20045220A 2002-06-20 2004-11-29 Heterocykliske forbindelser, farmasoytiske preparater innholdende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom NO330043B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (2)

Publication Number Publication Date
NO20045220L true NO20045220L (no) 2005-01-19
NO330043B1 NO330043B1 (no) 2011-02-07

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045220A NO330043B1 (no) 2002-06-20 2004-11-29 Heterocykliske forbindelser, farmasoytiske preparater innholdende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom

Country Status (14)

Country Link
US (2) US7084160B2 (no)
EP (1) EP1513818B1 (no)
JP (1) JP4477492B2 (no)
AR (1) AR040272A1 (no)
AT (1) ATE455767T1 (no)
AU (1) AU2003251559A1 (no)
DE (1) DE60331061D1 (no)
ES (1) ES2337246T3 (no)
IS (1) IS7599A (no)
NO (1) NO330043B1 (no)
PE (1) PE20040581A1 (no)
PL (1) PL374272A1 (no)
TW (1) TW200401638A (no)
WO (1) WO2004001059A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP2267117A3 (en) * 2002-06-27 2011-07-13 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
PT1506203E (pt) * 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2531859C (en) * 2003-07-11 2013-08-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole derivatives as raf kinase inhibitors
EP1684750B1 (en) * 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
CA2603826C (en) 2005-04-04 2013-03-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2007067257A2 (en) 2005-12-02 2007-06-14 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
WO2007071422A2 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
AU2006328186A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Chemical compounds
CN103739515B (zh) 2006-02-14 2015-11-25 哈佛大学的校长及成员们 组蛋白去乙酰化酶抑制剂
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
EP2081928B1 (en) 2006-11-10 2014-02-26 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
CN101627027B (zh) * 2007-01-05 2013-06-19 百时美施贵宝公司 氨基吡唑激酶抑制剂
JP2010515708A (ja) 2007-01-12 2010-05-13 アブ サイエンス 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療
MX2010003606A (es) 2007-10-01 2010-07-02 Isis Pharmaceuticals Inc Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016018795A1 (en) * 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP4019515A1 (en) * 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2332325A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
BR0309669A (pt) * 2002-04-23 2005-03-01 Bristol Myers Squibb Co Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
WO2003091229A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6951859B2 (en) * 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
JP4477492B2 (ja) 2010-06-09
NO330043B1 (no) 2011-02-07
AU2003251559A1 (en) 2004-01-06
IS7599A (is) 2004-12-15
ATE455767T1 (de) 2010-02-15
TW200401638A (en) 2004-02-01
PE20040581A1 (es) 2004-09-08
AR040272A1 (es) 2005-03-23
WO2004001059A2 (en) 2003-12-31
ES2337246T3 (es) 2010-04-22
AU2003251559A8 (en) 2004-01-06
US7084160B2 (en) 2006-08-01
JP2005533808A (ja) 2005-11-10
US20040077696A1 (en) 2004-04-22
WO2004001059A3 (en) 2004-03-04
EP1513818A4 (en) 2006-10-04
US7547711B2 (en) 2009-06-16
PL374272A1 (en) 2005-10-03
EP1513818B1 (en) 2010-01-20
EP1513818A2 (en) 2005-03-16
DE60331061D1 (de) 2010-03-11
US20060135576A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
NO20045220L (no) Heterocykliske inhibitorer for kinaser
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20050636L (no) Inhibitorer av tyrosinkinaser
NO20050072L (no) Nye inhibitorer av kinaser
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
EP1704145A4 (en) SELECTIVE KINASEINHIBITORS
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
DK1501508T3 (da) Inhibitorer af histondeatylase
EP1509507A4 (en) INHIBITORS OF MITOTIC KINESINE
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
EP1660436A4 (en) cathepsin inhibitors
DK1811998T3 (da) Triazoler anvendelige som inhibitorer af proteinkinaser
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1496897A4 (en) Tyrosine kinase inhibitor
EP1515727A4 (en) (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION
DE60319836D1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
AU2003268464A8 (en) Indole-type derivatives as inhibitors of p38 kinase
EP1697381A4 (en) INHIBITORS OF MITOTIC KINESINE
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees